PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT

• Wilma Barcellini,
• Marc Michel,
• Adam Cuker,
• Nichola Cooper,
• Waleed Ghanima,
• Raymond Wong,
• Francesco Zaja,
• Fengkui Zhang,
• Vladimir Bezlyak,
• Thu Thuy Nguyen,
• Hanny Al-Samkari

Affiliations

Wilma Barcellini

1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Marc Michel

2 Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Department of Internal Medicine, Créteil, France

Adam Cuker

3 Perelman School of Medicine, University of Pennsylvania, Department of Medicine and Department of Pathology and Laboratory Medicine, Philadelphia, PA, United States

Nichola Cooper

4 Imperial College London, Department of Inflammation and Immunity, London, United Kingdom

Waleed Ghanima

5 Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Raymond Wong

6 The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Shatin, Hong Kong

Francesco Zaja

7 DSM, University of Trieste and Department of Hematology, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy

Fengkui Zhang

8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Vladimir Bezlyak

9 Novartis, Basel, Switzerland

Thu Thuy Nguyen

10 Novartis, Paris, France

Hanny Al-Samkari

11 Harvard Medical School, Massachusetts General Hospital, Division of Hematology Oncology, Boston, MA, United States